AlTi Global Inc. significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 54.7% in the first quarter, selling 12,779 shares to hold a remaining position of 10,563 shares valued at $1.085 million. This move contrasts with several other institutional investors who increased their holdings during the same period. Brighton Jones LLC added 4,755 shares, while major entities like the Canada Pension Plan Investment Board boosted their positions by 25.6%, acquiring an additional 292,547 shares valued at $195.267 million.
Abbott Laboratories recently reported strong quarterly financial results, beating analyst expectations with earnings per share of $1.31 against a consensus of $1.28 and revenue of $12.51 billion, which represented a 13% year-over-year increase. The company also provided forward guidance for Q3 2026 EPS between $1.38 and $1.46 and full-year 2026 EPS between $5.45 and $5.60. Analysts maintain a generally positive outlook, with an average price target of $118.61 and ratings ranging from Strong Buy to Hold.
Corporate insiders have also demonstrated confidence in the company's prospects through recent stock purchases. CFO Philip P. Boudreau acquired 2,200 shares at an average cost of $91.50, while Director Daniel J. Starks purchased 10,000 shares for a total transaction value of $926,500. The company recently declared a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record as of July 15th, reflecting an annualized yield of 2.5%.
📉 AlTi Global reduced Abbott stake by 54.7% to 10,563 shares.
📈 Canada Pension Plan added 292,547 shares worth $195.27 million.
💰 Q2 EPS hit $1.31, beating the $1.28 consensus estimate.
📊 Revenue surged 13% to reach $12.51 billion this quarter.
🎯 Analysts maintain a 'Moderate Buy' rating with an $118.61 target.
📉 AlTi Global Inc. decreased its Abbott Laboratories stake by 54.7%, reducing holdings from 23,342 shares to 10,563 shares.
📈 Canada Pension Plan Investment Board increased its position by 25.6%, adding 292,547 shares valued at $195.267 million.
💰 Abbott Laboratories reported Q2 EPS of $1.31, beating the consensus estimate of $1.28.
📊 Revenue for the quarter reached $12.51 billion, marking a 13% increase compared to the prior year.
🎯 Analysts set an average price target of $118.61 with a general 'Moderate Buy' consensus rating.
💵 The company declared a quarterly dividend of $0.63 per share, yielding 2.5% annually.
👔 CFO Philip P. Boudreau purchased 2,200 shares at an average price of $91.50.
🏛️ Director Daniel J. Starks acquired 10,000 shares for a total value of $926,500.
📅 Q3 2026 EPS guidance is set between $1.38 and $1.46 per share.
🏥 Abbott operates globally through diagnostics, medical devices, nutritionals, and pharmaceuticals.
Bullish Signals
Beat earnings with EPS of $1.31 vs $1.28 consensus.
Revenue rose 13% YoY to $12.51 billion quarterly sales.
Institutional investor CPP Investment Board increased stake by 25.6%.
Insiders purchased shares signaling strong confidence in the stock.
Analysts target price of $118.61 above current trading price.
Risk Factors
AlTi Global Inc. cut Abbott position by 54.7% in Q1.
Jefferies lowered Abbott price target from $145 to $135.
Sanford Bernstein cut Abbott target from $125 to $110.
Bullish Signals
Abbott Laboratories beat quarterly earnings expectations with EPS of $1.31 versus the consensus of $1.28.
The company achieved a 13% year-over-year revenue increase, reporting $12.51 billion in quarterly sales.
Major institutional investor Canada Pension Plan Investment Board increased its stake by 25.6%.
CFO Philip P. Boudreau and Director Daniel J. Starks recently purchased shares, signaling insider confidence.
Analysts maintain an average price target of $118.61, which is above the current trading price.
The company provided solid forward guidance for Q3 2026 EPS between $1.38 and $1.46.
Risk Factors
AlTi Global Inc. significantly reduced its position in Abbott Laboratories by 54.7% during the first quarter.
Jefferies Financial Group lowered its price objective from $145.00 to $135.00, though maintaining a 'buy' rating.
Sanford C. Bernstein reduced its price target from $125.00 to $110.00 while keeping an 'outperform' rating.
Equities analysts have issued mixed signals regarding Abbott Laboratories (NYSE:ABT) ahead of its fiscal year 2026 earnings, with Erste Group Bank reducing its full-year EPS estimate to $5.47 from $5.48 and Raymond James Financial cutting its price target to $115. Conversely, JPMorgan Chase raised its objective to $120 with an 'overweight' rating, while Goldman Sachs lowered its target to $113 but maintained a 'buy' stance. The consensus rating remains a 'Moderate Buy' with a collective price target of $118.61.
Abbott Laboratories recently reported strong quarterly results, posting $1.31 in earnings per share which beat the consensus estimate of $1.28. Revenue reached $12.51 billion, representing a 13% year-over-year increase, though it slightly missed analyst expectations of $12.52 billion. The company achieved an 11.65% net margin and a return on equity of 17.65%, with guidance for the full fiscal year 2026 set between $5.45 and $5.60 per share.
Institutional ownership remains robust at 75.18%, highlighted by significant stake increases from Freemont Management S.A., which raised its holdings by 197.2% to own over 10,000 shares, and Thrivent Financial for Lutherans, which boosted its position by 24.3%. Company insiders also demonstrated confidence, with Director Daniel J. Starks purchasing $926,500 worth of stock and CFO Philip P. Boudreau acquiring an additional $201,300 in shares during the first quarter.
📉 Erste Group lowers FY2026 EPS forecast to $5.47 per share.
📈 JPMorgan raises price target to $120 with 'overweight' rating.
💰 Quarterly earnings beat estimates at $1.31 per share.
📊 Revenue surges 13% to reach $12.51 billion this quarter.
🏦 Freemont Management boosts stake by 197.2% in Q4.
📉 Erste Group Bank lowered its FY2026 EPS forecast for Abbott Laboratories to $5.47 per share from a previous estimate of $5.48.
📈 JPMorgan Chase increased its price target on ABT shares to $120.00 and assigned an 'overweight' rating in a recent research note.
💰 Abbott Laboratories reported quarterly earnings of $1.31 per share, surpassing the consensus estimate of $1.28 by $0.03.
📊 The company generated revenue of $12.51 billion for the quarter, marking a 13% increase compared to the same period last year.
🏦 Freemont Management S.A. significantly increased its stake in Abbott Laboratories by 197.2% during the fourth quarter.
💵 The company declared a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record on July 15th.
📉 Goldman Sachs reduced its price target from $121.00 to $113.00 while maintaining a 'buy' rating on the stock.
🎯 The consensus analyst price target for Abbott Laboratories is currently set at $118.61 with a 'Moderate Buy' overall rating.
📈 Abbott Laboratories has established full-year 2026 earnings guidance ranging from $5.45 to $5.60 per share.
👔 Director Daniel J. Starks purchased 10,000 shares of the company's stock for a total transaction value of $926,500.
Bullish Signals
Beat EPS expectations at $1.31 vs $1.28 consensus.
Revenue grew 13% YoY to $12.51 billion.
JPMorgan raised target to $120 with 'overweight' rating.
Freemont increased holdings by 197.2%.
Thrivent added $30M stake, boosting position 24.3%.
Offers 2.5% dividend yield with $2.52 annual payout.
ROE stands at 17.65% and net margin at 11.65%.
Risk Factors
Erste Group Bank FY2026 EPS estimate cut to $5.47.
Goldman Sachs price target lowered from $121.00 to $113.00.
Raymond James Financial price target cut from $130.00 to $115.00.
Barclays price target decreased from $144.00 to $143.00.
Quarterly revenue of $12.51 billion missed expectations.
Bullish Signals
Abbott Laboratories beat quarterly earnings expectations with $1.31 EPS compared to the consensus of $1.28.
The company achieved a strong revenue growth of 13% year-over-year, reaching $12.51 billion for the quarter.
JPMorgan Chase raised its price target to $120 and assigned an 'overweight' rating, indicating bullish sentiment.
Freemont Management S.A. increased its holdings by 197.2%, signaling strong institutional confidence in the stock.
Thrivent Financial for Lutherans boosted its stake by 24.3%, adding over $30 million to its position.
The company maintains a healthy dividend yield of 2.5% with an annualized payout of $2.52 per share.
Abbott Laboratories reported a solid return on equity of 17.65% and a net margin of 11.65%.
Risk Factors
Erste Group Bank reduced its FY2026 EPS estimate to $5.47, slightly below the consensus forecast of $5.48.
Goldman Sachs lowered its price target from $121.00 to $113.00, reflecting a more cautious valuation outlook.
Raymond James Financial cut its price target significantly from $130.00 to $115.00 despite maintaining an 'outperform' rating.
Barclays decreased its price target from $144.00 to $143.00, indicating a narrowing of the upside potential.
Quarterly revenue of $12.51 billion slightly missed analyst expectations of $12.52 billion.
Citigroup has raised its price target for Abbott Laboratories (NYSE:ABT) to $112.00 from $108.00, maintaining a 'buy' rating and indicating potential upside of 11.21% from the previous close. This move follows a mixed analyst landscape where Raymond James Financial lowered their target to $115.00 with an 'outperform' rating, while Bank of America reduced theirs to $102.00. Sanford C. Bernstein also cut their target to $110.00 but kept an 'outperform' stance, whereas Mizuho reduced their target to $115.00 and assigned a 'neutral' rating.
Abbott Laboratories recently reported quarterly earnings on July 16th, delivering $1.31 in EPS which beat the consensus estimate of $1.28 by $0.03. Revenue reached $12.51 billion, slightly missing the $12.52 billion consensus but growing 13.0% year-over-year. The company achieved a net margin of 11.65% and a return on equity of 17.65%. For the current fiscal year, management has guided EPS between $5.45 and $5.60, while analysts average an expectation of $5.48.
Corporate insider activity shows Director Daniel J. Starks purchasing 10,000 shares at an average price of $92.65, increasing his stake by 0.15% to a total value exceeding $625 million. CFO Philip P. Boudreau also bought 2,200 shares for approximately $201,300. Institutional ownership remains high at 75.18%, with several funds like MidAtlantic Capital Management and Cornerstone Financial Management acquiring new positions in the fourth quarter.
📈 Citigroup raises Abbott target to $112 with 'buy' rating.
💰 Q3 EPS beat consensus at $1.31 vs expected $1.28.
📊 Revenue grew 13% year-over-year to reach $12.51 billion.
👔 Director buys 10,000 shares worth over $926,000.
🏦 Institutional ownership stands at 75.18% with new stakes.
📈 Citigroup raises Abbott Laboratories price target to $112.00 from $108.00 with a 'buy' rating.
📉 Raymond James Financial lowers target to $115.00 while Bank of America cuts objective to $102.00.
💰 Q3 EPS beat consensus at $1.31 versus an expected $1.28.
📊 Revenue grew 13.0% year-over-year to reach $12.51 billion for the quarter.
🎯 Company guidance set for Q3 2026 EPS between $1.38 and $1.46.
👔 Director Daniel J. Starks buys 10,000 shares worth over $926,000.
💼 CFO Philip P. Boudreau acquires 2,200 shares for approximately $201,300.
🏦 Institutional ownership stands at 75.18% with new stakes from multiple funds.
📉 Consensus analyst target price averages $118.61 based on MarketBeat data.
🔬 Company operates globally in diagnostics, medical devices, nutritionals, and pharmaceuticals.
Bullish Signals
Citigroup raised target to $112.00, implying 11.21% upside.
Abbott beat EPS by $0.03 at $1.31/share.
Revenue surged 13.0% YoY to $12.51 billion.
Director bought 10,000 shares at $92.65 average price.
CFO acquired 2,200 shares for $201,300 total cost.
Risk Factors
Bank of America lowered price objective to $102.00.
Raymond James Financial reduced target from $130.00 to $115.00.
Mizuho Securities cut target to $115.00 with neutral rating.
Bullish Signals
Citigroup increased its price target to $112.00, signaling confidence in the stock's upside potential of 11.21% from the previous close.
Abbott Laboratories beat quarterly EPS estimates by $0.03, reporting $1.31 per share against a consensus of $1.28.
Revenue grew robustly by 13.0% year-over-year to reach $12.51 billion, demonstrating strong top-line growth.
Director Daniel J. Starks purchased 10,000 shares at an average price of $92.65, increasing his total holdings significantly.
CFO Philip P. Boudreau bought 2,200 shares for $201,300, indicating insider confidence in the company's future prospects.
The company maintains healthy financial metrics with a net margin of 11.65% and a return on equity of 17.65%.
Risk Factors
Bank of America reduced its price objective to $102.00, suggesting some analysts see limited upside or potential headwinds.
Raymond James Financial lowered their price target from $130.00 to $115.00, indicating a more cautious outlook compared to previous valuations.
Mizuho Securities cut its target to $115.00 and assigned a 'neutral' rating, reflecting uncertainty about future performance.
Abbott Laboratories (NYSE:ABT) shares opened significantly higher, gapping up from a previous close of $89.27 to $95.29 following the release of better-than-expected quarterly earnings. The company reported earnings per share (EPS) of $1.31, surpassing analyst consensus estimates of $1.28 by $0.03. Revenue for the quarter reached $12.51 billion, which was slightly below the specific expectation of $12.52 billion but represented a robust 13.0% year-over-year increase compared to the same period last year.
The healthcare giant demonstrated strong profitability metrics with a net margin of 11.65% and a return on equity of 17.65%. Looking ahead, Abbott has provided guidance for the third quarter of 2026 ranging from $1.38 to $1.46 per share in EPS, and full-year fiscal 2026 guidance between $5.45 and $5.60 per share. Additionally, the company announced a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record as of July 15th.
Analyst sentiment remains mixed but generally positive regarding the stock's trajectory. While several major firms including Sanford C. Bernstein, Evercore, UBS Group, and Mizuho recently lowered their price targets in April reports, maintaining 'outperform' or 'buy' ratings, the consensus rating from MarketBeat is currently a 'Moderate Buy' with a target price of $118.61. Institutional ownership remains high at 75.18%, with significant recent buying activity from large investors like Norges Bank and J. Stern & Co. LLP.
📈 Abbott shares gapped up to open at $95.29 after Q3 EPS beat.
💰 Revenue hit $12.51 billion, a 13.0% increase year-over-year.
🔮 FY 2026 guidance set between $5.45 and $5.60 per share.
🏦 Norges Bank initiated a new $2.9 billion position in stock.
📉 Major analysts lowered price targets despite recent earnings beat.
📈 Abbott Laboratories shares gapped up to open at $95.29 after reporting Q3 EPS of $1.31, beating analyst estimates of $1.28.
💰 Revenue for the quarter totaled $12.51 billion, marking a 13.0% increase compared to the same quarter last year.
📊 The company achieved a net margin of 11.65% and a return on equity of 17.65% during the reporting period.
🔮 Q3 2026 EPS guidance is set between $1.38 and $1.46, with full-year FY 2026 guidance ranging from $5.45 to $5.60.
💵 A quarterly dividend of $0.63 per share was announced, resulting in a 2.5% annualized dividend yield for investors.
📉 Analyst price targets were recently lowered by Sanford C. Bernstein ($125 to $110), Evercore ($134 to $120), and UBS Group ($158 to $135).
🏦 Institutional ownership stands at 75.18%, with Norges Bank initiating a new position valued at approximately $2.9 billion.
📈 J. Stern & Co. LLP significantly increased its stake by over 12,000% in the fourth quarter to own nearly 39.3 million shares.
🏢 The company has a market capitalization of $175.41 billion and trades at a P/E ratio of 32.59.
📉 The current consensus price target from MarketBeat is $118.61 with a 'Moderate Buy' rating based on analyst data.
Bullish Signals
EPS of $1.31 beat estimates by $0.03.
Revenue grew 13.0% year-over-year to $12.51 billion.
Net margin is 11.65% with ROE of 17.65%.
Norges Bank initiated; J. Stern & Co. stake up 12,000%.
$0.63 quarterly dividend offers a 2.5% yield.
Risk Factors
UBS cut target from $158 to $135.
Sanford Bernstein lowered target from $125 to $110.
Revenue of $12.51B missed $12.52B expectation.
Bullish Signals
Abbott Laboratories reported EPS of $1.31, which exceeded the consensus estimate of $1.28 by $0.03.
Revenue grew by 13.0% year-over-year to reach $12.51 billion for the quarter.
The company maintains a healthy net margin of 11.65% and a return on equity of 17.65%.
Institutional investors like Norges Bank initiated new positions, while J. Stern & Co. LLP increased its stake by over 12,000% in the last quarter.
The company announced a quarterly dividend of $0.63 per share with a 2.5% yield.
Risk Factors
Several major analysts recently lowered their price targets, including UBS Group reducing its target from $158 to $135 and Sanford C. Bernstein cutting it from $125 to $110.
Quarterly revenue of $12.51 billion was slightly below the specific analyst expectation of $12.52 billion.
Abbott Laboratories (NYSE:ABT) is trading at a forward P/E of 17x with shares down significantly from analyst targets, despite posting four consecutive earnings beats and maintaining its status as an S&P 500 Dividend Aristocrat. The company has successfully pivoted toward high-growth medical devices, with the FreeStyle Libre continuous glucose monitor franchise generating $2.08 billion in Q1 2026 alone, representing a 13.8% quarter-over-quarter increase.
The firm recently closed its approximately $21 billion acquisition of Exact Sciences on March 23, 2026, creating a new Cancer Diagnostics unit anchored by Cologuard. Management projects this strategic move will drive roughly $3 billion in incremental sales for 2026, while established pharmaceuticals and international segments also posted double-digit growth rates.
While the market still views Abbott as a defensive bond proxy due to its low beta of 0.607 and long dividend history, CEO Robert Ford argues this narrative underprices the company's transformation. Challenges remain in the Nutrition segment, which fell 6% year-over-year, alongside competitive pressures from DexCom and macroeconomic factors like foreign exchange fluctuations and China procurement policies.
📈 Q1 EPS beat at $1.15 vs full-year guidance of $5.38-$5.58.
💉 FreeStyle Libre CGM cleared $2.08B, growing 13.8% in Q1.
🏥 Exact Sciences acquisition closed for $21B with $3B incremental sales.
📉 Nutrition segment declined 6.0% due to price adjustments and volume recovery.
⚖️ Shares down 32.1% but analysts target $116.54 with 54-year dividend growth.
📈 Abbott Laboratories posted four consecutive EPS beats with adjusted Q1 2026 EPS reaching $1.15 against guidance of $5.38 to $5.58 for the full year.
💉 The FreeStyle Libre CGM franchise cleared $2.08 billion in Q1 2026, growing 13.8% as the global market is projected to expand from 12 million to 80 million users.
🏥 Abbott closed its $21 billion acquisition of Exact Sciences on March 23, 2026, launching a Cancer Diagnostics unit expected to generate $3 billion in incremental 2026 sales.
📉 The Nutrition segment declined 6.0% to $2.02 billion in Q1 2026, reflecting deliberate price adjustments and volume recovery strategies under CEO Robert Ford.
📊 Shares closed at $89.27, down 32.1% over one year, yet analysts maintain a buy consensus with a target price of $116.54.
⚖️ The company maintains a low beta of 0.607 and has increased dividends for 54 consecutive years, reinforcing its identity as a defensive dividend aristocrat.
Bullish Signals
Abbott beat Q1 2026 EPS of $1.15 with four consecutive wins.
FreeStyle Libre revenue hit $2.08 billion, up 13.8% in Q1 2026.
Pharmaceuticals grew 13.2% while international sales rose 11.3%.
Exact Sciences acquisition adds $3 billion incremental sales for 2026.
Risk Factors
Nutrition segment fell 6.0% to $2.02B due to price cuts.
Shares down 32.1% vs consensus, suggesting undervaluation concerns.
Abbott delivered four consecutive earnings beats with Q1 2026 adjusted EPS of $1.15, demonstrating consistent execution despite market headwinds.
The FreeStyle Libre CGM franchise generated $2.08 billion in revenue for Q1 2026, growing 13.8% and capturing a rapidly expanding global market.
Established Pharmaceuticals grew 13.2% while international sales rose 11.3%, indicating strong diversification beyond the Nutrition segment.
The $21 billion Exact Sciences acquisition is expected to contribute approximately $3 billion in incremental sales for 2026, validating the strategic pivot toward oncology diagnostics.
Risk Factors
The Nutrition segment, a core legacy business, fell 6.0% year-over-year to $2.02 billion due to deliberate price reductions and volume challenges.
Shares are trading at a significant discount to analyst consensus, down 32.1% over the past year, suggesting the market may still undervalue the company's transformation.
The company faces genuine competitive pressure from DexCom in the CGM space, which could impact FreeStyle Libre's long-term growth trajectory.
Abbott Laboratories (ABT) is scheduled to report its second-quarter earnings on July 16, with analysts projecting healthy top-line and bottom-line growth. The market expects earnings per share (EPS) to increase by approximately 1.6% to reach $1.28 per share, while revenue is forecasted to rise by 12.4% to $12.52 billion.
Analyst consensus indicates mixed revisions for the upcoming report, with EPS estimates trending downward despite revenue expectations showing varied adjustments. Baird specifically predicts that Abbott's MedTech segment will accelerate growth to meet the low end of management's full-year guidance range of 6.5% to 7.5%, while the MedDevices segment is expected to achieve top-line growth between 8% and 10%.
A key driver for Abbott's future revenue potential is its acquisition of Exact Sciences, which aims to expand the company's market presence in colorectal cancer screening. The integration of Exact's CancerGuard with Cologuard MCED test is projected to boost short-to-medium-term revenues, potentially growing annual revenue from approximately $3 billion toward or beyond $5 billion if the market fully embraces the new multi-cancer early detection technology.
Overall, the article highlights a positive outlook for Abbott Laboratories driven by strong segment performance and strategic acquisitions. Investors are watching closely how the company executes on its guidance amidst mixed analyst sentiment regarding specific earnings estimates.
📅 Abbott reports Q2 earnings July 16 before market open.
💰 Analysts expect EPS to reach $1.28 and revenue $12.52B.
📉 EPS estimates revised down while revenue revisions remain mixed.
🚀 Exact Sciences acquisition aims to boost short-to-medium-term revenues.
🧬 CancerGuard test could grow revenue from $3bn toward $5bn.
📅 Abbott Laboratories (ABT) is due to report Q2 earnings on July 16 before market open.
💰 Analysts expect EPS to rise by 1.6% to $1.28 per share and revenue to increase by 12.4% to $12.52 billion.
📉 EPS estimates have mostly been revised downward while revenue estimates show mixed revisions among analysts.
🚀 Baird predicts MedTech revenue growth will accelerate to meet the low end of management's full-year guidance (6.5%-7.5%).
🩺 MedDevices segment is expected to achieve 8%-10% top-line growth due to the breadth of product offerings.
🤝 The acquisition of Exact Sciences is a major strategic move expected to boost short-to-medium-term revenues.
🧬 Exact's CancerGuard with Cologuard MCED test could grow revenue from ~$3bn toward or beyond $5bn annually.
📈 This growth depends on the market embracing the new multi-cancer early detection technology effectively.
Bullish Signals
Analysts expect healthy top- and bottom-line growth for Abbott.
MedTech segment predicted to accelerate revenue growth.
MedDevices forecasted to achieve 8%-10% top-line growth.
Management's full-year guidance for MedTech appears achievable.
Risk Factors
Revenue estimates show mixed analyst revisions, indicating top-line uncertainty.
Bullish Signals
Analysts expect healthy top- and bottom-line growth for Abbott Laboratories in the upcoming Q2 earnings report.
MedTech segment is predicted to accelerate revenue growth, potentially meeting the low end of management's full-year guidance.
MedDevices segment is forecasted to achieve 8%-10% top-line growth driven by a broad product portfolio.
The Exact Sciences acquisition offers significant upside potential, with revenue from the combined MCED test expected to grow from ~$3bn toward or beyond $5bn annually.
Management's full-year guidance for MedTech (6.5%-7.5%) appears achievable based on current analyst predictions.
Risk Factors
Revenue estimates show mixed revisions among analysts, suggesting uncertainty about the magnitude of top-line performance.
Healthcare sector analysts have expressed bullish sentiment toward Abbott Laboratories (ABT), GE Healthcare Technologies Inc (GEHC), and Rani Therapeutics Holdings (RANI). TD Cowen analyst Josh Jennings reaffirmed a Buy rating on Abbott, setting a price target of $115.00, while Robert W. Baird initiated coverage with a Buy rating and a $121.00 target. The consensus for Abbott remains Strong Buy with an average price target of $117.95, suggesting approximately 25.5% upside from recent trading levels.
Analysts also maintain positive outlooks for GE Healthcare Technologies Inc and Rani Therapeutics Holdings. Jefferies analyst Matthew Taylor kept a Buy rating on GEHC with a $90.00 price target, supported by BTIG's recent Buy assignment at $75.00. For Rani Therapeutics, Canaccord Genuity and H.C. Wainwright both issued Buy ratings with targets of $5.00 and $11.00 respectively, reflecting a strong Street consensus that implies significant potential upside from current market prices.
The article aggregates analyst ratings and price targets provided by TipRanks, highlighting the collective optimism for these healthcare equities. While specific financial metrics like revenue or earnings are not detailed in this text, the focus remains on the strength of analyst recommendations and the implied valuation gaps between current stock prices and consensus targets.
📈 TD Cowen rates Abbott Buy with $115 price target.
📊 Robert W. Baird initiates Abbott Buy at $121 target.
🎯 Abbott consensus shows 25.5% upside to $117.95 average.
🚀 Rani Therapeutics Street implies massive 986.3% upside potential.
📈 TD Cowen analyst Josh Jennings maintains a Buy rating on Abbott Laboratories with a $115.00 price target.
📊 Robert W. Baird initiated coverage on Abbott Laboratories with a Buy rating and a $121.00 price target.
🎯 Abbott Laboratories holds a Strong Buy consensus with an average price target of $117.95, implying 25.5% upside.
🏥 Jefferies analyst Matthew Taylor maintains a Buy rating on GE Healthcare Technologies Inc at $90.00.
💰 BTIG assigned a Buy rating to GE Healthcare Technologies Inc with a $75.00 price target.
🚀 Canaccord Genuity analyst Edward Nash maintains a Buy rating on Rani Therapeutics Holdings at $5.00.
📉 H.C. Wainwright maintained a Buy rating on Rani Therapeutics Holdings with an $11.00 price target.
🔍 The Street consensus for Rani Therapeutics implies 986.3% upside from current levels.
📝 TipRanks aggregates analyst data to track performance and momentum in the healthcare sector.
Bullish Signals
Multiple top firms issued Buy ratings on Abbott, GE, and Rani.
Abbott has Strong Buy consensus with $117.95 target (25.5% upside).
Rani has Strong Buy consensus with $7.50 target (986.3% upside).
Analysts cite strong sector optimism and solid company fundamentals.
Bullish Signals
TD Cowen, Robert W. Baird, Jefferies, BTIG, Canaccord Genuity, and H.C. Wainwright have all issued Buy ratings on Abbott Laboratories, GE Healthcare Technologies Inc, or Rani Therapeutics Holdings.
Abbott Laboratories has a Strong Buy consensus with an average price target of $117.95, representing 25.5% upside from current levels.
Rani Therapeutics Holdings has a Strong Buy Street consensus with an average price target of $7.50, implying 986.3% upside from current prices.
Analysts covering these healthcare stocks cite strong sector optimism and specific company fundamentals supporting their bullish ratings.
Absher Wealth Management LLC significantly increased its position in Abbott Laboratories (NYSE:ABT) by 68.9% in the first quarter, purchasing an additional 135,846 shares to own a total of 333,127 shares valued at $34.2 million. This move makes ABT the fund's 10th largest holding, representing 4.0% of its portfolio. Other major institutional investors also adjusted their stakes recently, including Freemont Management raising its position by 197.2%, PFA Pension establishing a new stake worth $116.58 million, and Danica Pension acquiring a new position valued at approximately $185.64 million.
Analyst sentiment remains mixed but generally positive regarding the company's buy rating despite recent price target reductions from major banks. Goldman Sachs, Benchmark, JPMorgan Chase, Bank of America, and Mizuho all lowered their price targets in April and June, with consensus targets ranging between $102 and $145. However, the aggregate analyst consensus remains a 'Moderate Buy' with an average price target of $118.42. The stock currently trades around $93.97, trading below its 200-day moving average of $103.09 but above its 50-day moving average of $89.21.
Financially, Abbott Laboratories reported strong quarterly performance with revenue of $11.16 billion, beating estimates by $174 million and growing 7.8% year-over-year. The company posted earnings per share of $1.15, slightly exceeding the consensus estimate of $1.14, while maintaining a net margin of 13.90% and a return on equity of 17.62%. Management has provided guidance for FY 2026 EPS between $5.38 and $5.58, with analysts predicting an average consensus of $5.48 for the current year.
The company declared a quarterly dividend of $0.63 per share payable on August 17th to shareholders of record on July 15th, offering a yield of 2.7% and an annualized payout of $2.52. Insider activity includes Director Daniel J. Starks purchasing 10,000 shares for $926,500 and CFO Philip P. Boudreau buying 2,200 shares for $201,300. Abbott Laboratories operates globally through diagnostics, medical devices, nutritionals, and pharmaceuticals, maintaining a market capitalization of $163.69 billion with a debt-to-equity ratio of 0.56.
📈 Absher Wealth Management increased ABT stake 68.9% to $34.2M in Q1.
💰 Abbott reported Q1 revenue of $11.16B, beating estimates by $174M.
📊 EPS reached $1.15 with a net margin of 13.90%.
💵 Quarterly dividend declared at $0.63/share for 2.7% yield.
👔 Insiders bought shares: Director Starks (10k) and CFO Boudreau (2.2k).
📈 Absher Wealth Management increased its ABT stake by 68.9% in Q1, adding 135,846 shares to reach a total holding of 333,127 shares valued at $34.2 million.
🏦 Major institutional investors including PFA Pension ($116.58M new stake) and Danica Pension ($185.64M new stake) initiated or significantly increased positions in the fourth quarter.
💰 Abbott Laboratories reported Q1 revenue of $11.16 billion, a 7.8% year-over-year increase that beat analyst estimates by $174 million.
📊 The company posted earnings per share of $1.15, surpassing the consensus estimate of $1.14 with a net margin of 13.90% and ROE of 17.62%.
🎯 Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $118.42, despite recent downward revisions from Goldman Sachs, JPMorgan, and Bank of America.
💵 The board declared a quarterly dividend of $0.63 per share payable on August 17th, providing a yield of 2.7% to shareholders of record on July 15th.
📉 Stock price action shows ABT trading at $93.97, currently below its 200-day moving average of $103.09 but above its 50-day moving average of $89.21.
👔 Insider buying activity was recorded with Director Daniel Starks purchasing 10,000 shares for $926,500 and CFO Philip Boudreau acquiring 2,200 shares for $201,300.
📅 Management provided FY 2026 EPS guidance ranging from $5.38 to $5.58, with analysts forecasting a consensus of $5.48 for the fiscal year.
🏥 Abbott operates through four main segments: diagnostics, medical devices, nutritionals, and established pharmaceuticals, serving hospitals, clinics, and direct-to-consumer channels.
Bullish Signals
Absher Wealth added 135,846 shares to a $34.2M holding.
PFA Pension established a new stake worth $116.58 million.
Danica Pension initiated a new position valued at $185.64 million.
Freemont Management raised its stake by 197.2% in Q4.
Thrivent Financial boosted its position by 24.3% to own 246,586 shares.
Abbott Laboratories reported Q1 revenue of $11.16 billion, up 7.8%.
Company beat EPS estimates with $1.15 versus consensus of $1.14.
Revenue exceeded expectations by $174 million.
FY 2026 guidance for EPS between $5.38 and $5.58.
Quarterly dividend of $0.63 per share with 2.7% yield.
Risk Factors
Major banks lowered ABT price targets from $120-$145 to $102-$120.
Goldman Sachs cut target from $121 to $113 maintaining buy rating.
JPMorgan Chase dropped target from $123 to $110 with overweight rating.
Bank of America decreased target from $120 to $102 in June note.
Mizuho lowered objective from $125 to $115 issuing neutral rating.
Stock trades at $93.97 below 200-day moving average of $103.09.
Bullish Signals
Absher Wealth Management increased its position by 68.9% in Q1, adding 135,846 shares to a total holding of 333,127 shares valued at $34.2 million.
PFA Pension established a new stake worth approximately $116.58 million, while Danica Pension initiated a new position valued at roughly $185.64 million.
Freemont Management raised its stake by 197.2% in Q4, and Thrivent Financial boosted its position by 24.3% to own 246,586 shares.
Abbott Laboratories reported Q1 revenue of $11.16 billion, which represents a 7.8% increase compared to the same quarter last year.
The company beat analyst earnings estimates with EPS of $1.15 versus a consensus of $1.14 and revenue exceeding expectations by $174 million.
Management provided FY 2026 guidance for EPS between $5.38 and $5.58, indicating continued growth expectations.
The company declared a quarterly dividend of $0.63 per share with an annualized yield of 2.7% payable on August 17th.
Director Daniel J. Starks purchased 10,000 shares for $926,500, and CFO Philip P. Boudreau bought 2,200 shares for $201,300.
Risk Factors
Major investment banks including Goldman Sachs, JPMorgan Chase, Bank of America, and Mizuho recently lowered their price targets on ABT stock.
Goldman Sachs reduced its target price from $121.00 to $113.00 while maintaining a 'buy' rating in a report dated May 27th.
Benchmark lowered its price target from $145.00 to $120.00 and set a 'buy' rating on April 17th.
JPMorgan Chase dropped its price target from $123.00 to $110.00 with an 'overweight' rating in a report from April 17th.
Bank of America decreased its price target from $120.00 to $102.00 in a research note dated June 12th.
Mizuho lowered its price objective from $125.00 to $115.00 and issued a 'neutral' rating on April 17th.
The stock is currently trading at $93.97, which is below its 200-day moving average of $103.09.
Arbor Capital Management Inc. ADV established a new position in Abbott Laboratories (NYSE:ABT) during the first quarter, purchasing 26,518 shares valued at approximately $2.69 million. This acquisition represents about 2.2% of Arbor's portfolio, making it the firm's eighth-largest holding. Several other institutional investors also increased their stakes in the healthcare giant, including DMC Group LLC, GreatBanc Trust CO, Meadow Creek Wealth Advisors LLC, Peterson Wealth Services, and Griffin Asset Management Inc., which collectively raised their positions by varying percentages ranging from 4.7% to 22.8%.
Analyst sentiment remains mixed but generally positive regarding Abbott's fundamentals. Brokerages like TD Cowen, Jefferies Financial Group, Sanford C. Bernstein, and Benchmark maintained or upgraded their 'buy' ratings despite lowering price targets to an average consensus of $118.42. Daiwa Securities Group downgraded the stock to 'neutral' with a lower target. The company recently reported quarterly earnings that beat analyst expectations, posting $1.15 per share on revenue of $11.16 billion, which was up 7.8% year-over-year.
Abbott Laboratories continues to provide shareholder value through its dividend program and maintains a strong balance sheet. The company declared a quarterly dividend of $0.63 per share, payable on August 17th for shareholders of record on July 15th, resulting in an annualized yield of 2.7%. Financial metrics show a debt-to-equity ratio of 0.56 and a market capitalization of $163.69 billion. Additionally, Director Daniel J. Starks and CFO Philip P. Boudreau executed insider purchases, further signaling confidence in the company's long-term prospects.
📈 Arbor Capital bought 26,518 Abbott shares worth $2.69 million.
💰 Earnings beat estimates at $1.15/share with $11.16B revenue.
💵 Quarterly dividend of $0.63 offers a 2.7% annualized yield.
👔 Executives Starks and Boudreau purchased shares for ownership.
📈 Arbor Capital Management Inc. ADV initiated a new position by buying 26,518 shares of Abbott Laboratories valued at approximately $2.69 million.
📊 Multiple institutional investors including DMC Group LLC and Griffin Asset Management Inc. increased their holdings in the first quarter.
💰 Abbott Laboratories reported quarterly earnings of $1.15 per share, beating the consensus estimate of $1.14 by $0.01.
📈 Revenue for the quarter reached $11.16 billion, representing a 7.8% increase compared to the same period last year.
💵 The company declared a quarterly dividend of $0.63 per share with an annualized yield of 2.7% payable on August 17th.
📉 TD Cowen lowered its price target from $137.00 to $115.00 while maintaining a 'buy' rating for the stock.
📉 Jefferies Financial Group decreased its price objective from $145.00 to $135.00 but retained a 'buy' recommendation.
📉 Daiwa Securities Group cut its rating from 'outperform' to 'neutral' and set a target price of $92.00.
📉 Sanford C. Bernstein reduced its target price from $125.00 to $110.00 while keeping an 'outperform' rating.
📉 Benchmark lowered its price target from $145.00 to $120.00 and assigned a 'buy' rating to the shares.
👔 Director Daniel J. Starks acquired 10,000 shares at an average price of $92.65, increasing his direct ownership by 0.15%.
👔 CFO Philip P. Boudreau purchased 2,200 shares at an average cost of $91.50 in a transaction valued at $201,300.
📊 The company maintains a debt-to-equity ratio of 0.56 and a current ratio of 1.39 indicating solid liquidity.
📈 Abbott Laboratories has set full-year 2026 earnings guidance between $5.38 and $5.58 per share.
🏥 The global healthcare company operates through diagnostics, medical devices, nutritionals, and established pharmaceuticals.
Bullish Signals
Arbor Capital Management Inc. ADV initiated new position with $2.69 million purchase.
Institutional investors increased holdings in first quarter.
Beat quarterly earnings expectations with $1.15 per share.
Revenue grew 7.8% year-over-year to reach $11.16 billion.
Quarterly dividend of $0.63 per share with 2.7% yield.
Insider purchases by Director and CFO indicate confidence.
Analysts maintain consensus Moderate Buy rating.
Return on equity of 17.62% and net margin of 13.90%.
Risk Factors
TD Cowen cut target to $115.00.
Jefferies lowered objective to $135.00.
Daiwa downgraded to neutral at $92.00.
Bernstein reduced target to $110.00.
Benchmark cut target to $120.00.
Bullish Signals
Arbor Capital Management Inc. ADV initiated a new position in Abbott Laboratories, signaling institutional interest with a purchase of approximately $2.69 million.
Multiple other institutional investors including DMC Group LLC, GreatBanc Trust CO, and Griffin Asset Management Inc. increased their holdings during the first quarter.
Abbott Laboratories beat quarterly earnings expectations with $1.15 per share compared to the consensus estimate of $1.14.
Revenue grew 7.8% year-over-year to reach $11.16 billion, demonstrating solid top-line growth in the healthcare sector.
The company declared a quarterly dividend of $0.63 per share with an annualized yield of 2.7%, providing income to shareholders.
Director Daniel J. Starks and CFO Philip P. Boudreau executed insider purchases, indicating confidence from top management and board members.
Analysts maintain a consensus 'Moderate Buy' rating with three Strong Buy ratings and nineteen Buy ratings among the analysts covering the stock.
The company reported a return on equity of 17.62% and a net margin of 13.90%, reflecting efficient operations and profitability.
Risk Factors
TD Cowen lowered its price target from $137.00 to $115.00, suggesting potential downside risk relative to previous valuations.
Jefferies Financial Group decreased its price objective from $145.00 to $135.00, indicating a more conservative valuation outlook.
Daiwa Securities Group downgraded the stock from 'outperform' to 'neutral' with a lower target price of $92.00.
Sanford C. Bernstein reduced its target price from $125.00 to $110.00, reflecting a cautious stance on near-term performance.
Benchmark lowered its price target from $145.00 to $120.00, signaling a reduction in expected upside potential.
Abbott has launched the FreeStyle Libre 3 Sensor in the US, a coin-sized continuous glucose monitoring device designed for wear on the upper arm. The FDA-cleared sensor offers up to 14 days of continuous monitoring and is positioned as the company's smallest and thinnest CGM unit to date. It streams real-time interstitial glucose data directly to the FreeStyle Libre 3 app, providing minute-by-minute readings and trend arrows to help patients manage their diabetes without routine fingersticks.
The product is marketed primarily through retail and mail-order pharmacies as a prescription item, with Abbott highlighting that most commercially insured US patients pay less than $75 per month. Medicare coverage is available for eligible beneficiaries using insulin who meet specific program requirements. The device relies on smartphone connectivity rather than a dedicated reader, requiring compatible iOS or Android devices, and is indicated for patients aged 4 and older.
Abbott identifies its diabetes care portfolio, including the FreeStyle Libre line, as a key growth engine in its investor presentations. The company cites studies indicating that continuous glucose monitoring helps reduce HbA1c levels and time spent in hypoglycemia for insulin-using patients with Type 1 and Type 2 diabetes. While the article focuses on product features and market access rather than specific financial results, it reinforces the strategic importance of this portfolio to Abbott's stock narrative.
💰 Most insured patients pay under $75/month or $0 with coverage.
📱 Real-time glucose streams directly to smartphone app, no reader needed.
🩺 Abbott cites Libre portfolio as primary growth engine in investor updates.
🔬 Studies show reduced HbA1c and hypoglycemia for insulin-using patients.
📅 FreeStyle Libre 3 Sensor is now available in the US with FDA clearance for up to 14 days of continuous wear on the upper arm.
💰 Most commercially insured patients pay under $75/month, while many pay $0 if they meet specific insurance coverage criteria.
📱 The device streams real-time glucose data directly to a smartphone app, eliminating the need for a dedicated reader device.
🩺 Abbott positions diabetes care, including the Libre portfolio, as a primary growth engine in its investor presentations.
🔬 Clinical studies cited by Abbott suggest the technology reduces HbA1c and hypoglycemia time for insulin-using patients.
⚖️ The sensor competes with Dexcom and Medtronic but differentiates through a pharmacy-based distribution model and lower monthly costs.
📉 Shares of Abbott (NYSE: ABT) are linked to the company's broader narrative that Libre 3 is a concrete product driver, though not the sole stock story.
Bullish Signals
FreeStyle Libre 3 is smallest/thinnest CGM sensor.
Pharmacy model offers lower monthly costs vs rivals.
Clinical data shows reduced HbA1c and hypoglycemia time.
Ascentis Independent Advisors significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 132.4% during the first quarter, adding 10,792 shares to a total holding of 18,945 shares valued at $1.945 million. Several other institutional investors, including Cornerstone Financial and MidAtlantic Capital, also established new positions in the fourth quarter, while insider trading data reveals Director Daniel J. Starks purchased 10,000 shares for $926,500 and CFO Philip P. Boudreau acquired an additional 2,200 shares.
Abbott Laboratories reported strong quarterly financial results on April 16th, posting earnings per share (EPS) of $1.15 against a consensus estimate of $1.14. The company generated revenue of $11.16 billion, representing a 7.8% year-over-year increase, with net margins at 13.90% and a return on equity of 17.62%. Management has provided guidance for fiscal year 2026 EPS between $5.38 and $5.58, and Q2 2026 EPS between $1.25 and $1.31.
The company announced a quarterly dividend of $0.63 per share payable on August 17th to shareholders of record on July 15th, resulting in an annualized yield of 2.6%. Analyst sentiment remains mixed with recent price target reductions from major firms like JPMorgan Chase and Bank of America, though the stock maintains a 'Moderate Buy' average rating with a consensus price target of $118.42.
📈 Ascentis Advisors raised Abbott position by 132.4% to $1.9M value.
💰 Q1 EPS beat estimates at $1.15 on $11.16B revenue growth.
🏦 Institutional ownership is 75.18% with new stakes from Cornerstone Financial.
👔 Director Daniel Starks bought 10,000 shares for $926,500 total.
💸 Quarterly dividend declared at $0.63 per share ex-date July 15th.
📈 Ascentis Independent Advisors raised its position in Abbott Laboratories by 132.4% in Q1, acquiring an additional 10,792 shares.
💰 The fund's total holding is now valued at $1,945,000 according to the latest SEC Form 13F filing.
📊 Abbott Laboratories reported Q1 EPS of $1.15, beating analyst estimates by $0.01.
💵 Revenue reached $11.16 billion, marking a 7.8% increase compared to the same quarter last year.
🏦 Institutional ownership stands at 75.18%, with several firms like Cornerstone Financial initiating new stakes.
👔 Director Daniel J. Starks purchased 10,000 shares for a total transaction value of $926,500.
💸 The company declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 15th.
📉 JPMorgan Chase reduced its price target from $123.00 to $110.00 while maintaining an 'overweight' rating.
📉 Bank of America cut its price target from $120.00 to $102.00 in a report dated June 12th.
🎯 The consensus analyst price target for the stock is currently set at $118.42 with an average 'Moderate Buy' rating.
Bullish Signals
Beat earnings with $1.15 EPS vs $1.14 consensus.
Revenue grew 7.8% YoY to $11.16 billion.
Net margin of 13.90% and ROE of 17.62%.
Investor Ascentis increased stake by over 130%.
Director bought $926,500 shares showing confidence.
Risk Factors
JPMorgan cut target to $110.00.
Bank of America lowered target to $102.00.
Benchmark Financial reduced objective to $120.00.
Bullish Signals
Abbott Laboratories beat quarterly earnings expectations, reporting $1.15 EPS versus a consensus of $1.14.
Revenue grew by 7.8% year-over-year to reach $11.16 billion, demonstrating solid top-line growth.
The company maintains healthy profitability metrics with a net margin of 13.90% and a return on equity of 17.62%.
Major institutional investor Ascentis Independent Advisors significantly increased its stake by over 130% in Q1.
Director Daniel J. Starks executed a $926,500 buy order, signaling continued insider confidence in the stock.
Risk Factors
JPMorgan Chase reduced its price target from $123.00 to $110.00, indicating potential downside pressure.
Bank of America lowered its price target from $120.00 to $102.00, reflecting a more cautious outlook.
Benchmark Financial cut its price objective from $145.00 to $120.00 despite reaffirming a 'buy' rating.
Abbott Laboratories (ABT) shares rose on Wednesday following an analyst rating upgrade from Baird, which initiated coverage with an Outperform rating and a $121 price target. The firm highlighted a stable growth trajectory for the medical technology company, driven by a series of upcoming catalysts expected to support its business performance.
Baird's positive outlook suggests confidence in Abbott's ability to navigate current market conditions and capitalize on future opportunities within the MedTech sector. This analyst initiation serves as a key driver for the stock's recent price appreciation, reflecting broader investor interest in the company's strategic positioning.
📈 Baird initiates Abbott coverage with Outperform rating.
💰 $121 price target implies upside potential for ABT.
🚀 Stable growth driven by multiple upcoming catalysts.
🏥 Abbott identified as leading MedTech company.
📅 Positive sentiment realized on Wednesday trading session.
📈 Abbott Laboratories (ABT) shares gained value after Baird initiated coverage with an Outperform rating.
💰 Baird set a $121 price target for ABT, implying upside potential from current levels.
🚀 The analyst firm cites a stable growth trajectory driven by multiple upcoming catalysts.
🏥 Abbott is identified as a leading MedTech company with strong future prospects.
📅 The positive sentiment was realized on Wednesday trading session.
Abbott Laboratories (NYSE: ABT) saw institutional investor Canoe Financial LP acquire a new stake of 40,000 shares in the first quarter, valued at approximately $4.1 million, according to recent SEC 13F filings. Several other hedge funds adjusted their positions during the same period, with American National Bank of Texas reducing holdings by 2.4% while Park Place Capital Corp and Clayton Financial Group LLC increased theirs by 11.0% and 1.4%, respectively. Institutional ownership remains high at 75.18%.
The company's stock opened at $94.02, trading below its 200-day moving average of $105.27 but above its 50-day average of $89.08. Key financial metrics include a market capitalization of $163.77 billion, a P/E ratio of 26.34, and a debt-to-equity ratio of 0.56. Abbott recently declared a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record on July 15th, representing an annualized yield of 2.7%.
Analyst sentiment is mixed with recent target price adjustments from major firms like Mizuho, Evercore, and Benchmark lowering their objectives to around $115-$120, though BTIG maintains a buy rating at $131. The consensus rating is 'Moderate Buy' with an average target price of $118.30. Notably, CFO Philip P. Boudreau purchased 2,200 shares and Director Daniel J. Starks bought 10,000 shares in April, signaling insider confidence.
📈 Canoe Financial LP bought 40,000 shares worth $4.1 million in Q1.
💰 Abbott declared a $0.63 quarterly dividend with a 2.7% yield.
📊 Stock trades at a P/E of 26.34 with a $163.77 billion market cap.
👤 CFO and Director insiders purchased shares totaling over $900,000 recently.
🔍 Analysts split on targets ranging from $115 to $131 per share.
📈 Canoe Financial LP acquired 40,000 shares of Abbott Laboratories ($ABT) in Q1, valued at approximately $4.1 million.
📉 American National Bank of Texas reduced its stake by 2.4% to 3,408 shares, while Park Place Capital Corp increased its position by 11.0%.
💰 Abbott Laboratories declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 15th and a yield of 2.7%.
📊 The stock trades at a P/E ratio of 26.34 with a market cap of $163.77 billion and a debt-to-equity ratio of 0.56.
📉 Mizuho, Evercore, and Benchmark lowered their price targets to between $115 and $120, citing recent market conditions.
🔍 BTIG Research reaffirmed a 'buy' rating with a target price of $131.00, contrasting with the bearish moves from other analysts.
👤 CFO Philip P. Boudreau purchased 2,200 shares at an average cost of $91.50, demonstrating insider buying activity.
👤 Director Daniel J. Starks acquired 10,000 shares for a total transaction value of $926,500 in late April.
🏢 Abbott Laboratories operates through diagnostics, medical devices, nutritionals, and established pharmaceuticals globally.
📉 The stock opened at $94.02, trading below its 200-day simple moving average of $105.27.
A federal court has denied Abbott Laboratories' motion to dismiss a lawsuit alleging its PediaSure marketing made unsupported claims regarding children's growth. This procedural victory for plaintiffs allows the case to proceed to discovery, depositions, and potentially trial, signaling that a judge found sufficient legal merit in the allegations. The litigation specifically targets the grey area between permissible structure/function claims and implied disease or developmental outcomes under FDA regulations.
The lawsuit reactivates reputational risks for Abbott's nutrition segment, which has already suffered significant damage from the 2022 Similac infant-formula recall that shuttered a major Michigan plant. Analysts are now evaluating whether this fresh legal proceeding over a separate flagship brand will erode the division's earnings quality and pricing power, as PediaSure relies heavily on premium positioning and parental trust.
While Abbott's medical devices arm, particularly its FreeStyle Libre franchise, continues to deliver consistent double-digit volume growth, the nutrition segment remains exposed. The broader implication extends across the pediatric and adult nutrition category, potentially affecting global peers like Danone and Reckitt if a precedent is set on permissible growth-related language. The market currently views this isolated litigation risk as unlikely to be a primary thesis-breaker unless a large adverse judgment or class-action certification occurs.
🏛️ Court allows PediaSure lawsuit over unsupported growth claims to proceed.
📉 Reputational risks compound after 2022 Similac recall damage.
💰 Premium brand trust faces litigation headlines and liability exposure.
🌐 Industry peers face potential tighter compliance costs from precedent.
⚠️ Nutrition division risk outweighs medical device arm growth strength.
🏛️ A federal court ruled Abbott Laboratories must face a lawsuit alleging PediaSure marketing made unsupported claims about children's growth.
⚖️ The denial of the motion to dismiss allows plaintiffs to proceed with discovery, depositions, and potential trial regarding FDA compliance boundaries.
📉 The litigation reactivates reputational risks for Abbott's nutrition segment following the acute damage from the 2022 Similac infant-formula recall.
🔍 Discovery could surface internal documents showing if Abbott knowingly stretched advertising boundaries, increasing liability exposure.
💰 PediaSure competes on premium positioning and parental trust, assets that are highly sensitive to litigation headlines.
🌐 A precedent set in this case could tighten compliance costs industry-wide for peers like Danone and Reckitt's Mead Johnson.
📈 Abbott's bull case remains anchored in its medical devices arm, specifically the FreeStyle Libre franchise with consistent double-digit volume growth.
⚠️ The real risk is reputational compounding from two high-profile nutrition controversies in four years potentially repricing the division's brand premium.
📊 ABT last traded near $94.12, with a composite signal reading neutral based on price momentum and news flow.
⏳ The discovery phase is expected to dominate the narrative for at least the next several quarters.
Modest nutrition earnings contribution insulates stock from litigation risks.
Early low-cost settlement would quickly clear stock overhang.
Risk Factors
Abbott faces lawsuit over unsupported PediaSure growth claims.
FDA compliance risks increase as plaintiffs proceed with discovery.
Reputational damage from 2022 Similac recall compounds litigation risk.
Internal documents may reveal knowingly stretched advertising boundaries.
Premium brand trust threatened by two nutrition controversies in four years.
Bullish Signals
Abbott's medical devices arm, specifically the FreeStyle Libre franchise, has delivered consistent double-digit volume growth.
The market currently assigns a more modest earnings contribution to the nutrition segment, insulating the overall stock from isolated litigation risks in that division.
A counter-scenario of an early settlement at a contained cost would quickly clear the overhang on the stock.
Risk Factors
A federal court ruled Abbott Laboratories must face a lawsuit alleging PediaSure marketing made unsupported claims about children's growth.
The denial of the motion to dismiss allows plaintiffs to proceed with discovery, depositions, and potential trial regarding FDA compliance boundaries.
The litigation reactivates reputational risks for Abbott's nutrition segment following the acute damage from the 2022 Similac infant-formula recall.
Discovery could surface internal documents showing if Abbott knowingly stretched advertising boundaries, increasing liability exposure.
PediaSure competes on premium positioning and parental trust, assets that are highly sensitive to litigation headlines.
The real risk is reputational compounding from two high-profile nutrition controversies in four years potentially repricing the division's brand premium.
The discovery phase is expected to dominate the narrative for at least the next several quarters.
Abbott Laboratories (NYSE:ABT) saw institutional ownership shifts in the first quarter, led by Aaron Wealth Advisors LLC reducing its position by 53.3% to hold 13,746 shares valued at $1.41 million. Conversely, several smaller institutional investors increased their stakes, including American National Bank of Texas and Nia Impact Advisors LLC, while hedge funds collectively own 75.18% of the company's stock.
Company insiders also made notable purchases, with Director Daniel J. Starks buying 10,000 shares for $926,500 in April, bringing his total holding to over 6.7 million shares worth approximately $625 million. CFO Philip P. Boudreau purchased an additional 2,200 shares at an average price of $91.50, signaling continued insider confidence in the stock despite recent institutional selling.
Financially, Abbott reported strong quarterly results with revenue of $11.16 billion, beating estimates by $174 million and posting EPS of $1.15 versus a consensus of $1.14. The company provided FY 2026 guidance ranging from $5.38 to $5.58 per share and declared a quarterly dividend of $0.63 per share, payable on August 17th with an ex-dividend date of July 15th.
The healthcare giant operates through diagnostics, medical devices, nutritionals, and pharmaceuticals, maintaining a market cap of $163.77 billion and a P/E ratio of 26.34. With a debt-to-equity ratio of 0.56 and a current ratio of 1.39, the company presents a solid balance sheet as it continues to expand its portfolio of medical products and services globally.
📉 Aaron Wealth Advisors reduced Abbott holdings by 53.3% to $1.41 million.
📈 Multiple funds increased stakes, with Park Place Capital rising 11.0%.
💰 Director Daniel Starks bought 10,000 shares for $926,500.
📊 Q1 revenue hit $11.16 billion, beating estimates by $174 million.
💸 Quarterly dividend of $0.63 per share payable August 17th.
📉 Aaron Wealth Advisors LLC reduced its Abbott Laboratories position by 53.3% in Q1, selling 15,701 shares while retaining 13,746 shares valued at $1.41 million.
📈 American National Bank of Texas increased its stake by 2.4% to own 3,408 shares worth $427,000 during the fourth quarter.
📈 Nia Impact Advisors LLC grew its holdings by 2.2% in Q2, now owning 3,706 shares valued at $504,000.
📈 Park Place Capital Corp increased its position by 11.0% in Q4 to hold 815 shares worth $102,000.
📈 Lantern Wealth Advisors LLC raised its stake by 1.7% in Q3 to own 5,028 shares valued at $674,000.
📈 Clayton Financial Group LLC lifted its holdings by 1.4% in Q4 to own 6,217 shares worth $779,000.
💰 Director Daniel J. Starks purchased 10,000 shares for $926,500 on April 27th, increasing his total ownership to 6,751,103 shares valued at over $625 million.
💰 CFO Philip P. Boudreau bought 2,200 shares for $201,300 on April 23rd at an average price of $91.50 per share.
📊 Abbott Laboratories reported Q1 revenue of $11.16 billion, beating the consensus estimate of $10.99 billion by $174 million.
💹 The company posted EPS of $1.15, surpassing analyst expectations of $1.14 and showing a 7.8% year-over-year revenue increase.
📅 Abbott Laboratories provided FY 2026 guidance of $5.38-$5.58 EPS and Q2 2026 guidance of $1.25-$1.31 EPS.
💸 The company declared a quarterly dividend of $0.63 per share, payable on August 17th with an ex-dividend date of July 15th.
🏦 Abbott Laboratories maintains a market cap of $163.77 billion and a P/E ratio of 26.34 as of the latest trading session.
📉 The stock trades at a fifty-day moving average of $89.08 and a 200-day moving average of $105.38, with a current price of $94.02.
🛡️ The company holds a healthy balance sheet with a debt-to-equity ratio of 0.56 and a current ratio of 1.39.
Bullish Signals
Revenue beat estimates by $174M at $11.16B.
EPS exceeded consensus at $1.15 versus $1.14.
Revenue grew 7.8% year-over-year with solid top-line growth.
Director Starks bought $926,000 worth of shares.
CFO Boudreau purchased 2,200 shares to reinforce support.
FY 2026 EPS guidance set between $5.38 and $5.58.
Quarterly dividend of $0.63 offers a 2.7% yield.
Low debt-to-equity ratio of 0.56 with strong current ratio.
Risk Factors
Major advisor cut position by 53.3%, selling over 15,000 shares.
Stock trades below 50-day ($94.02) and 200-day ($105.38) averages.
Bullish Signals
Abbott Laboratories beat quarterly revenue estimates by $174 million, reporting $11.16 billion versus the consensus of $10.99 billion.
The company exceeded earnings expectations with EPS of $1.15 compared to the analyst consensus of $1.14.
Revenue grew 7.8% year-over-year, demonstrating solid top-line growth in the healthcare sector.
Director Daniel J. Starks purchased over $926,000 worth of shares, signaling strong insider confidence in the company's future prospects.
CFO Philip P. Boudreau added to his personal holdings by purchasing 2,200 shares, further reinforcing insider support.
The company provided clear forward guidance for FY 2026 EPS between $5.38 and $5.58, aligning with analyst predictions of $5.48.
Abbott Laboratories declared a quarterly dividend of $0.63 per share, offering investors a yield of 2.7% and demonstrating commitment to shareholder returns.
The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.56 and a strong current ratio of 1.39.
Risk Factors
Aaron Wealth Advisors LLC significantly reduced its position by 53.3% in the first quarter, selling over 15,000 shares.
The stock price is currently trading below both its fifty-day and 200-day moving averages at $94.02 versus $89.08 and $105.38 respectively.
Abbott Laboratories (ABT) shares rose 3.12% on June 25, outperforming the broader Healthcare Services & Equipment sector which gained 1.70%. The stock's upward momentum was driven by a combination of strategic partnerships, strong analyst support, and its status as a resilient dividend aristocrat attracting investors rotating into stable healthcare giants amid market volatility.
Key catalysts include a global licensing agreement with ALZpath to develop a blood-based Alzheimer's diagnostic test using Abbott's Alinity platforms, enhancing its advanced diagnostic portfolio. Additionally, the medical devices segment remains a growth driver, specifically the FreeStyle Libre continuous glucose monitoring platform, which is supported by positive clinical trial data from the FreeDM2 trial and expanding European partnerships.
Wall Street analysts maintain bullish ratings, citing Abbott's history of over fifty consecutive years of dividend increases and its current undervaluation. The company recently scheduled its second-quarter earnings release for July, with market anticipation focused on guidance updates regarding core divisions and the integration of recent acquisitions like Exact Sciences.
📈 Abbott stock rose 3.12%, outperforming the healthcare sector on June 25.
🤝 Global licensing deal integrates pTau217 antibody tech for Alzheimer's detection.
💰 Analysts rate overweight, citing 50+ years of dividend increases and undervaluation.
⚠️ Exact Sciences acquisition may dilute fiscal 2026 EPS by $0.20.
📉 CGM growth slowed to 7.5% amid international tender delays.
📈 Abbott Laboratories (ABT) stock price increased by 3.12% on June 25, outperforming the Healthcare Services & Equipment sector.
🤝 The company signed a global licensing agreement with ALZpath to integrate pTau217 antibody technology into Alinity diagnostics for Alzheimer's detection.
🩸 Strong sales of the FreeStyle Libre continuous glucose monitoring platform and positive FreeDM2 trial data drive growth in the diabetes care division.
📊 Analysts maintain overweight ratings, highlighting a history of over fifty consecutive years of dividend increases and current stock undervaluation.
💰 The company recently scheduled its second-quarter earnings release for July, anticipating guidance updates on core divisions.
⚠️ Integration of the $21 billion Exact Sciences acquisition is expected to dilute adjusted fiscal 2026 EPS by approximately $0.20.
📉 Growth in the continuous glucose monitoring (CGM) segment slowed to 7.5% due to delayed international tender renewals and tough year-over-year comparatives.
🇨🇳 Ongoing policy shifts and volume-based procurement pricing pressures in China's diagnostics market threaten margins and constrain growth.
📉 The Nutrition segment experienced a 6.0% volume-led sales drop, forcing promotional pricing cuts to revive demand.
🦠 Rapid and molecular diagnostics sales fell by 10% due to a significantly weaker post-pandemic respiratory virus testing season.
Bullish Signals
Stock rose 3.12% on June 25, outperforming sector gain of 1.70%.
Secured global licensing agreement with ALZpath for Alzheimer's diagnostic test.
Strong FreeStyle Libre sales and positive FreeDM2 study data drive growth.
Analysts bullish citing 50+ years of consecutive dividend increases.
Substantial undervaluation with average price target of $117.68.
Risk Factors
Exact Sciences acquisition dilutes fiscal 2026 EPS by $0.20.
CGM growth slowed to 7.5% amid tender delays and tough comparatives.
Dexcom and Medtronic competition decelerates CGM franchise growth.
Nutrition segment sales dropped 6.0% due to volume decline.
Molecular diagnostics sales fell 10% on weak respiratory testing.
Bullish Signals
Abbott Laboratories stock rose 3.12% on June 25, outperforming the broader Healthcare Services & Equipment sector which gained 1.70%.
The company secured a global licensing agreement with ALZpath to develop a blood-based Alzheimer's diagnostic test, significantly enhancing its advanced diagnostic portfolio.
Strong FreeStyle Libre sales and positive clinical trial data from the FreeDM2 study demonstrate continued growth in the diabetes care division.
Wall Street analysts maintain bullish ratings, citing Abbott's history of over fifty consecutive years of dividend increases as a fundamental cushion for investors.
Analysts highlight the stock's substantial undervaluation, with an average price target of $117.68 compared to recent trading levels.
Risk Factors
The integration and financing burdens of the $21 billion Exact Sciences acquisition are expected to dilute adjusted fiscal 2026 earnings per share by approximately $0.20.
Comparable growth in Abbott's continuous glucose monitoring (CGM) segment slowed to 7.5% due to delayed international tender renewals and tough year-over-year comparatives.
Intensifying competition from rivals Dexcom and Medtronic is contributing to the decelerating growth of the CGM franchise.
The Nutrition segment experienced a 6.0% volume-led sales drop, forcing the company to implement promotional pricing cuts to revive demand.
Rapid and molecular diagnostics sales fell by 10% due to a significantly weaker post-pandemic respiratory virus testing season.
Abbott Laboratories (NYSE:ABT) saw mixed institutional activity in the first quarter, with BI Asset Management reducing its stake by 20% to 70,805 shares. Conversely, major funds like J. Stern & Co., Norges Bank, Invesco Ltd., and Vanguard Group increased their holdings significantly, with Vanguard boosting its position to over 175 million shares worth approximately $22 billion.
Financially, Abbott reported strong Q1 results on April 16th, posting $1.15 EPS against a consensus of $1.14 and revenue of $11.16 billion, which beat estimates of $10.99 billion. The company achieved a 7.8% year-over-year revenue increase, maintaining a net margin of 13.90% and a return on equity of 17.62%. Management provided FY 2026 EPS guidance between $5.38 and $5.58.
Analyst sentiment remains cautiously positive despite some price target reductions from firms like UBS and Wells Fargo, which lowered targets to $135 and $109 respectively while maintaining buy or overweight ratings. The stock offers a 2.8% dividend yield with an upcoming payment of $0.63 per share to shareholders of record on July 15th.
Insider trading activity includes CFO Philip Boudreau purchasing 2,200 shares at $91.50 and Director Daniel Starks acquiring 10,000 shares at $92.65, indicating continued confidence from company leadership. Institutional ownership stands at 75.18%, with insiders holding an additional 0.46% of the outstanding stock.
📉 BI Asset Management sold 17,693 shares, holding $7.27M remaining.
🏦 Vanguard Group increased holdings to 175.56M shares valued at $22B.
💰 Q1 revenue hit $11.16B, beating estimates with 7.8% growth.
📊 EPS of $1.15 surpassed consensus; FY 2026 guidance set $5.38-$5.58.
📉 BI Asset Management reduced its Abbott Laboratories stake by 20.0% in Q1, selling 17,693 shares to hold a remaining position valued at $7.27 million.
📈 J. Stern & Co. LLP dramatically increased its position by 12,439.6% in Q4, acquiring over 39 million shares worth nearly $4.93 billion.
🏦 Vanguard Group boosted its holdings by 1.4% in Q4, now owning 175.56 million shares valued at approximately $22 billion.
💰 Abbott Laboratories reported Q1 revenue of $11.16 billion, beating analyst estimates of $10.99 billion and growing 7.8% year-over-year.
📊 The company posted earnings per share of $1.15, surpassing the consensus estimate of $1.14 with a net margin of 13.90%.
🎯 Management issued FY 2026 EPS guidance ranging from $5.38 to $5.58, slightly below the analyst consensus forecast of $5.48.
💵 A quarterly dividend of $0.63 per share is scheduled for payment on August 17th to shareholders of record on July 15th.
📉 Analyst price targets were lowered by UBS ($158 to $135), Wells Fargo ($122 to $109), and Stifel ($145 to $120) in recent reports.
👔 CFO Philip Boudreau purchased 2,200 shares at an average price of $91.50, while Director Daniel Starks bought 10,000 shares at $92.65.
📈 The stock maintains a consensus rating of 'Moderate Buy' with a MarketBeat consensus price target of $118.30.
Bullish Signals
Beat Q1 EPS expectations at $1.15 vs $1.14 consensus.
Revenue grew 7.8% to reach $11.16 billion.
Major investors like Vanguard increased their stakes.
Offers a healthy 2.8% dividend yield with $2.52 annual payout.
Insiders executed open market purchases signaling confidence.
Simply Wall St analysis suggests Abbott Laboratories (ABT) stock is currently undervalued by approximately 24%, trading at $88.41 per share against a calculated fair value of $116.54. The report highlights that despite a recent decline in total shareholder return of 32.16% over the past year, the company maintains a strong dividend track record and diversified healthcare business mix.
Analysts project Abbott's earnings to reach $9.5 billion by June 2029, representing significant growth from current levels, though there is notable disagreement on long-term potential with estimates ranging between $7.2 billion and $11.3 billion. The valuation model relies on steady top-line compounding, improving profitability margins, and a discount rate just under 8% to bridge the gap between current market price and fair value.
While the current P/E ratio of 24.6x is slightly above the US Medical Equipment industry average, it remains below an estimated fair ratio of 30.1x, suggesting potential for re-rating. However, the analysis warns that sustained pricing pressure in diagnostics, prolonged impacts from tariffs, and currency fluctuations could challenge the company's earnings path and undermine the current undervaluation narrative ahead of its July 16 earnings report.
📉 Stock trades at $88.41, a 24% discount to $116.54 fair value.
📈 Earnings forecast to reach $9.5 billion by June 2029.
💰 Quarterly dividend reaffirmed for steady investor income stream.
⚠️ Diagnostics pricing pressure risks future earnings and margins.
🌍 Tariffs and currency swings threaten global revenue growth.
📉 Abbott Laboratories stock is trading at $88.41, representing a 24% discount to a calculated fair value of $116.54.
📈 Analysts forecast earnings growth to $9.5 billion by June 2029, up from $6.3 billion today, with EPS expected to reach $5.45.
💰 The company has reaffirmed its quarterly dividend, providing a steady income stream for investors despite recent share price declines.
⚠️ Sustained pricing pressure in the diagnostics segment poses a potential risk to future earnings growth and margin expansion.
🌍 Macroeconomic headwinds including tariffs and currency swings could negatively impact Abbott's global revenue trajectory.
📊 The current P/E ratio of 24.6x is slightly elevated compared to the industry average of 24.4x but below a fair value estimate of 30.1x.
Bullish Signals
Undervalued by 24% with $116.54 fair value target.
Earnings grow to $9.5B by June 2029.
Robust dividend track record supports income strategies.
P/E ratio of 24.6x allows re-rating to 30.1x.
Risk Factors
Sustained pricing pressure could erode diagnostics margins.
Tariffs and currency fluctuations may disrupt global revenue.
Bearish estimates project only $7.2B earnings by 2029.
Bullish Signals
Stock is identified as undervalued by 24% with a fair value target of $116.54 versus the current price of $88.41.
Strong long-term earnings growth trajectory projected to reach $9.5 billion by June 2029 from current levels of $6.3 billion.
Company maintains a robust dividend track record which supports investor income strategies despite recent market volatility.
Current P/E ratio of 24.6x leaves room for re-rating towards an estimated fair value multiple of 30.1x.
Risk Factors
Sustained pricing pressure in the diagnostics segment could erode margins and challenge the projected earnings ramp.
Potential negative impact from tariffs and currency fluctuations may disrupt global revenue growth assumptions.
Significant analyst disagreement on long-term earnings potential, with bearish estimates as low as $7.2 billion by 2029.
Abbott Laboratories (NYSE:ABT) saw significant institutional activity in the fourth quarter, highlighted by a massive position increase from J. Stern & Co. LLP, which added over 39 million shares to its stake, bringing total ownership to nearly $4.9 billion. Other notable investors including Norges Bank, Invesco Ltd., Ninety One UK Ltd., and Vanguard Group Inc. also increased or established new positions in the healthcare giant during this period.
Financially, Abbott reported strong quarterly results with revenue of $11.16 billion, beating analyst estimates by $170 million. The company posted earnings per share (EPS) of $1.15, surpassing the consensus of $1.14, and achieved a 7.8% year-over-year revenue growth. Management has provided forward guidance for FY 2026 EPS between $5.38 and $5.58, with analysts expecting a group average of $5.48.
The company maintains a robust balance sheet with a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott recently announced a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record on July 15th, representing an annualized yield of 2.8%. Corporate insiders, including Director Daniel J. Starks and CFO Philip P. Boudreau, also made recent purchases in the stock.
📈 J. Stern & Co. stake surged 12,439% to $4.9 billion value.
🏦 Major investors like Norges Bank increased positions in Q4.
💰 Abbott Q1 revenue hit $11.16B, beating estimates by $170M.
📊 EPS of $1.15 exceeded expectations; FY 2026 guidance raised to $5.38-$5.58.
💵 $0.63 quarterly dividend declared with ex-date July 15th.
📈 J. Stern & Co. LLP dramatically increased its stake by 12,439.6% to own 39,319,009 shares valued at $4.9 billion.
🏦 Major institutional investors including Norges Bank, Invesco, and Vanguard all added new or increased positions in Q4.
💰 Abbott reported Q1 revenue of $11.16 billion, beating estimates by $170 million with 7.8% year-over-year growth.
📊 The company beat EPS expectations with a result of $1.15 versus the consensus estimate of $1.14.
🚀 Management raised FY 2026 guidance to an EPS range of $5.38-$5.58, exceeding analyst group expectations.
💵 A quarterly dividend of $0.63 per share was declared with an ex-dividend date of July 15th.
👔 Corporate insiders including the CFO and a Director purchased shares in April at prices near $92.
Bullish Signals
J. Stern & Co. increased position by over 39 million shares.
Abbott beat revenue and EPS estimates, showing operational strength.
Abbott Laboratories (ABT) is characterized as a strong buy due to its structural undervaluation and resilient fundamentals, despite recent negative price action. The stock currently trades at a 17.1% P/E ratio and a 35.1% sales multiple discount relative to peers. Discounted Cash Flow (DCF) fair value estimates suggest potential upside ranging from 21.8% to 39.4%.
Growth prospects for the company are driven by several key factors, including the acquisition of Exact Sciences, participation in diagnostics megatrends, and global expansion within Continuous Glucose Monitoring (CGM). Consequently, guidance for both sales and earnings per share (EPS) for fiscal year 2026 has been raised.
Analyst consensus remains bullish with forward one-year price targets averaging $116.32, supporting a potential re-rating of the stock. Like other medical device subsectors in healthcare, Abbott is viewed as resilient to broader macroeconomic swings that often affect the rest of the market.
📈 Strong buy rating due to structural undervaluation and resilient fundamentals.
💰 Trades at 17.1% P/E and 35.1% sales multiple discount vs peers.
🚀 DCF fair value implies 21.8–39.4% upside potential for the company.
🔬 Growth driven by Exact Sciences acquisition and diagnostics megatrends.
📊 FY26 guidance raised for both sales and earnings per share.
📈 Abbott Laboratories is rated a strong buy due to structural undervaluation and resilient fundamentals.
💰 The stock trades at a 17.1% P/E and 35.1% sales multiple discount compared to peers.
🚀 DCF fair value estimates imply 21.8–39.4% upside potential for the company.
🔬 Growth is underpinned by the Exact Sciences acquisition and diagnostics megatrends.
🌍 Global expansion in Continuous Glucose Monitoring (CGM) supports future revenue growth.
📊 FY26 guidance has been raised for both sales and earnings per share (EPS).
🎯 Analyst consensus is bullish with forward 1Y price targets averaging $116.32.
🛡️ Medical devices are noted as resilient to broader macroeconomic market swings.
Bullish Signals
Strong buy rating due to structural undervaluation.
Global CGM expansion provides strong growth vector.
FY26 guidance raised for sales and EPS.
Bullish consensus with $116.32 average price target.
Medical device subsector offers macroeconomic resilience.
Bullish Signals
Abbott Laboratories is rated a strong buy due to structural undervaluation and resilient fundamentals despite recent negative price action.
The stock trades at a significant discount to peers with a 17.1% P/E ratio and a 35.1% sales multiple discount.
DCF fair value estimates imply substantial upside ranging from 21.8% to 39.4%.
Growth is underpinned by the strategic Exact Sciences acquisition and diagnostics megatrends.
Global expansion in Continuous Glucose Monitoring (CGM) provides a strong growth vector.
FY26 guidance has been raised for both sales and EPS, indicating improved outlook.
Analyst consensus is bullish with forward 1Y price targets averaging $116.32.
The medical device subsector offers resilience against broader macroeconomic swings.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
